PD-1 immune checkpoint inhibitor
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PD-1 immune checkpoint inhibitor, covering 2024-06-04 to 2026-02-27. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations [Phase 1, Phase 2]